Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.9%

6 terminated/withdrawn out of 206 trials

Success Rate

88.9%

+2.3% vs industry average

Late-Stage Pipeline

20%

42 trials in Phase 3/4

Results Transparency

4%

2 of 48 completed trials have results

Key Signals

50 recruiting2 with results

Enrollment Performance

Analytics

N/A
67(48.2%)
Phase 4
22(15.8%)
Phase 3
20(14.4%)
Phase 2
17(12.2%)
Early Phase 1
8(5.8%)
Phase 1
5(3.6%)
139Total
N/A(67)
Phase 4(22)
Phase 3(20)
Phase 2(17)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (206)

Showing 20 of 206 trials
NCT07083349Early Phase 1Terminated

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

Role: collaborator

NCT07776873Phase 3Not Yet Recruiting

Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke

Role: lead

NCT07383909Not ApplicableRecruiting

Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery

Role: collaborator

NCT07602465Active Not Recruiting

The Impact of Blood Pressure Variability During the Induction and Surgical Periods on Postoperative Acute Kidney Injury

Role: collaborator

NCT07811895Not ApplicableNot Yet Recruiting

Dual GIP/GLP-1 Receptor Agonist in Obese Women Before Frozen Embryo Transfer

Role: collaborator

NCT07809178Not Yet Recruiting

China Treatment Trial for Tumor in Sellar Region With Unruptured Intracranial Aneurysm

Role: collaborator

NCT07186751Not ApplicableRecruiting

The Efficacy and Safety of Pregabalin Combined With Venlafaxine in Patients With Fibromyalgia

Role: collaborator

NCT07787325Not Yet Recruiting

Real-World Evaluation of Recombinant Human Prourokinase for Acute Ischemic Stroke Within 4.5 Hours

Role: lead

NCT07572903Not ApplicableCompleted

The Efficacy and Safety of Temporal Interference Stimulation on Motor Symptoms of Parkinson's Disease

Role: lead

NCT07748546Not ApplicableNot Yet Recruiting

The Rebound Effect on Repeated Low-Level Red Light Therapy for Myopia

Role: lead

NCT07744646Phase 1Not Yet Recruiting

Alpha-0261 Tablets for Moderate-to-Severe Ulcerative Colitis

Role: lead

NCT06434766Not ApplicableRecruiting

Multicenter iTBS Neuromodulation for PTSD Treatment

Role: collaborator

NCT07741318Not ApplicableActive Not Recruiting

ThromBus Aspiration for Acute Mesenteric Artery Occlusion With Emergent Laparoscopic Surgery

Role: collaborator

NCT05965687Phase 3Completed

Normobaric Hyperoxia Combined With Intravenous Thrombolysis for Acute Ischemic Stroke (OPENS-3)

Role: collaborator

NCT06331923Not ApplicableCompleted

Assessing the Effectiveness of Continuous Glucose Monitoring in Enhancing Surgical Outcomes for Patients With Diabetes

Role: collaborator

NCT07272499Phase 2Recruiting

Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk Disease

Role: collaborator

NCT07700537Not ApplicableRecruiting

Efficacy and Neural Mechanisms of Transcranial Direct Current Stimulation Targeting the Supplementary Motor Area for the Treatment of Subacute Post-stroke Aphasia

Role: lead

NCT07672210Recruiting

PregnAncy-Related Aortic DISsEction in China

Role: collaborator

NCT07703267Not ApplicableNot Yet Recruiting

Non-pharmacological Interventions for People With Mild Cognitive Impairment in the Community

Role: collaborator

NCT07697391Phase 4Not Yet Recruiting

AI-Assisted Lifestyle Intervention Versus Tirzepatide for Obesity and Newly Diagnosed Type 2 Diabetes

Role: lead